What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects with IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) Open Protocol code: CHK01-03 EudraCT code: No aplica Research group: Nephrology and kidney transplantation Service: Nephrology Principal investigator: Soler Romeo, Maria Jose Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Ensayo clínico exploratorio, multicéntrico, de intervención, prospectivo, aleatorizado, con doble enmascaramiento y controlado con placebo para evaluar la seguridad y la eficacia de AON-D21 en pacientes con neumonía extrahospitalaria grave Open Protocol code: S-D21-C300 EudraCT code: No aplica Research group: Shock, Organ Dysfunction and Resuscitation Service: RTA ICU Principal investigator: Ferrer Roca, Ricard Pathology: Codis per situacions especials Phase: Fase II Status: Recruiting volunteers Estudio en fase III multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo de la eficacia y la seguridad de tezepelumab en niños de 5 a <12 años con asma grave no controlada (HORIZON) Open Protocol code: D5180C00016 EudraCT code: No aplica Research group: Growth and Development Service: General Pediatrics and Specialties Principal investigator: de Mir Messa, Inés Pathology: Malalties del sistema respiratori Phase: Fase III Estudio de fase 2a, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de MK-6194 en participantes adultos con lupus eritematoso sistémico. Open Protocol code: MK-6194-006 EudraCT code: No aplica Research group: Rheumatology Service: Rheumatology Principal investigator: Cortes Hernandez, Josefina Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II [Randomised, double-blind, placebo-controlled study to investigate a single administration of BI 765845 on top of standard of care in patients with acute myocardial infarction Open Protocol code: 1478-0002 EudraCT code: No aplica Research group: Cardiovascular Diseases Service: Cardiology Principal investigator: García del Blanco, Bruno Pathology: Malalties del sistema circulatori Phase: Fase II Status: Recruiting volunteers A novel COMBinATorial therapy with albumin and enoxaparin in patients with decompensated cirrhosis at high-risk of poor outcome Open Protocol code: COMBAT EudraCT code: No aplica Research group: Liver Diseases Service: Hepatology Principal investigator: Genescà Ferrer, Joan Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Status: Recruiting volunteers A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants with Primary Biliary Cholangitis (PBC) Open Protocol code: CLIN-60190-454 EudraCT code: No aplica Research group: Liver Diseases Service: Hepatology Principal investigator: Villagrasa Vilella, Ares Aurora Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase III Status: Recruiting volunteers An open-label, multiple dose, multicenter study to evaluate the pharmacokinetics, safety, and tolerability of filgotinib in children and adolescents from 8 to less than 18 years of age with juvenile idiopathic arthritis Open Protocol code: GLPG0634-CL-131 EudraCT code: No aplica Research group: Rheumatology Service: Rheumatology Principal investigator: Lopez Corbeto, Mireia Phase: Fase I Status: Recruiting volunteers A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants Open Protocol code: MK-8591A-053 EudraCT code: No aplica Research group: Infectious Diseases Service: Infectious Principal investigator: Navarro Mercadé, Jordi Pathology: Malalties del sistema respiratori Phase: Fase II Status: Recruiting volunteers Ensayo multicéntrico en dos partes, Fase IIa /IIb, aleatorizado, doble-ciego, controlado frente a placebo, de grupos paralelos por rango de dosis, para evaluar la eficacia, seguridad y tolerabilidad de la combinación de zibotentan y dapaglifozina y dapaglifozina en monoterapia frente a placebo, en pacientes con cirrosis y características de hipertensión portal. Open Protocol code: D4326C00003 EudraCT code: No aplica Research group: Liver Diseases Service: Hepatology Principal investigator: Pons Delgado, Mònica Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Status: Recruiting volunteers A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in patients with moderately severe non-proliferative diabetic retinopathy Open Protocol code: RETISOM EudraCT code: No aplica Research group: Ophtalmology Service: Ophthalmology Principal investigator: Boixadera Espax, Ana Pathology: Malalties de l’ull i dels seus annexos Phase: Fase III Status: Recruiting volunteers Estudio de fase IIIb, global, multicéntrico, aleatorizado, doble ciego y de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de remibrutinib 25 mg b.i.d., en comparación con placebo, con omalizumab 300 mg cada 4 semanas como control activo, a lo largo de 52 semanas en pacientes adultos con UCE inadecuadamente controlada con antihistamínicos H1 de segunda generación. Open Protocol code: CLOU064A2304 EudraCT code: No aplica Research group: Systemic Diseases Service: Internal Medicine Principal investigator: Labrador Horrillo, Moisés Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase III Status: Recruiting volunteers Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad, la tolerabilidad y la inmunogenicidad de V116 en niños y adolescentes con un mayor riesgo de enfermedad neumocócica. Open Protocol code: V116-013 EudraCT code: No aplica Research group: Infection and Immunity in pediatric patients Service: General Pediatrics and Specialties Principal investigator: Soler Palacín, Pere Pathology: Certes malalties infeccioses i parasitàries Phase: Fase III Status: Recruiting volunteers Ensayo de extensión abierto multicéntrico para evaluar la eficacia, seguridad y tolerabilidad de HZN-825 en pacientes con esclerosis sistémica cutánea difusa Open Protocol code: HZNP-HZN-825-302 EudraCT code: 2021-006271-42 Research group: Systemic Diseases Service: Internal Medicine Principal investigator: Guillen Del Castillo, Alfredo Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Status: Recruiting volunteers Estudio en fase I/II de escalada de dosis para evaluar la seguridad, tolerabilidad y eficacia de VX-522 en pacientes a partir de 18 años con fibrosis quística y un genotipo del CFTR que no responde al tratamiento modulador del CFTR Open Protocol code: VX21-522-001 EudraCT code: No aplica Research group: Pneumology Service: Pneumology Principal investigator: Álvarez Fernandez, Antonio Pathology: Malalties del sistema respiratori Phase: Fase I A randomized, phase II, double-blind, placebo-controlled study to investigate the safety and efficacy of KER-012 in combination with background therapy in adult participants with pulmonary arterial hypertension (TROPOS Study) Open Protocol code: KER-012-A201 EudraCT code: _ Research group: Pneumology Service: Pneumology Principal investigator: López Meseguer, Manuel Pathology: Malalties del sistema respiratori Phase: Fase II A study evaluating the safety and efficacy of once-weekly dosing of somapacitan in a basket study design in paediatric participants with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome or idiopathic short stature. Open Protocol code: NN8640-4469 EudraCT code: No aplica Research group: Growth and Development Service: General Pediatrics and Specialties Principal investigator: Mogas Viñas, Eduard Pathology: Certes afeccions originades en el període perinatal Phase: Fase III Status: Recruiting volunteers A phase 3, multicentre, randomised, double-blind, vehicle-controlled, parallel-group study to evaluate, the efficacy and safety of tribanulib 10 mg, ointment applied to a treatment, field larger than 25 cm and up to 10 cm in adult patients with actinic keratosis. Open Protocol code: M-14867-33 EudraCT code: No aplica Research group: Biomedical Research in Melanoma Service: Dermatologia Principal investigator: Ferrándiz Pulido, Carla Pathology: Tumors Phase: Fase III Status: Recruiting volunteers Estudio de seguimiento a largo plazo de pacientes con MPS IIIA procedentes de ensayos clínicos de terapia génica que incluyen la administración de ABO-102 (scAAV9.U1a.hSGSH) Open Protocol code: LTFU-ABO-102 EudraCT code: 2019-002979-34 Research group: Pediatric Neurology Service: General Pediatrics and Specialties Principal investigator: Toro Riera, Mireia del Pathology: Malalties del sistema nerviós Phase: Fase III A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (ClairaflyTM) Open Protocol code: 1397-0013 EudraCT code: No aplica Research group: Pneumology Service: Pneumology Principal investigator: Álvarez Fernandez, Antonio Pathology: Malalties del sistema respiratori Phase: Fase II Status: Recruiting volunteers Pagination First page « Previous page ‹ … Page 1371 Page 1372 Current page 1373 Page 1374 Page 1375 … Next page › Last page »
